ClearPoint Neuro (CLPT) AI Stock Analysis

• Market Cap: $548.08M
• Dividend Yield: N/A
• Average Volume (3M): 734.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.57
• Revenue Growth: 19.68%
• EPS Growth: -13.17%
• Country: US
• Employees: 115
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.21
• Shares Outstanding: 28,427,418
• 10 Day Avg. Volume: 1,552,264
• 30 Day Avg. Volume: 734,027
• PEG Ratio: 0.99
• Price to Book (P/B): 16.37
• Price to Sales (P/S): 13.24
• P/FCF Ratio: -45.06
• Enterprise Value/Market Cap: 0.60
• Enterprise Value/Revenue: 9.86
• Enterprise Value/Gross Profit: 16.32
• Enterprise Value/Ebitda: -15.30
• 1Y Price Target: $25.00
• Price Target Upside: 26.65% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 60 Neutral
• Price Target: $20.00 ▲(1.32% Upside)

ClearPoint Neuro's strong revenue growth and strategic initiatives are promising, but profitability challenges and overbought technical indicators present risks. The company's solid cash position and strategic partnerships are positive, but valuation concerns due to ongoing losses weigh on the score.

Positive Factors

Revenue Growth

Consistent revenue growth across all segments indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Global Expansion

Global expansion and regulatory clearances enhance market reach and competitive positioning, providing a solid foundation for future growth.

Strong Cash Position

A strong cash position provides financial flexibility for strategic investments and operations, reducing reliance on external financing.

Negative Factors

Profitability Challenges

Ongoing losses and negative profit margins indicate challenges in achieving profitability, which could hinder long-term financial sustainability.

Increased Operating Expenses

Rising operating expenses may pressure margins and profitability, necessitating efficient cost management to maintain financial health.

Negative Operating Cash Flow

Negative operating cash flow suggests potential liquidity issues, impacting the company's ability to fund operations without external financing.

ClearPoint Neuro Business Overview & Revenue Model

Company Description

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

How the Company Makes Money

ClearPoint Neuro generates revenue through multiple streams, primarily from the sale of its neurosurgical navigation systems and disposables used in procedures. The company's revenue model includes direct sales to hospitals and surgical centers, as well as potential recurring revenue from consumable products associated with its systems. Furthermore, ClearPoint engages in partnerships with pharmaceutical companies for drug delivery applications and collaborates with research institutions for clinical trials, which may also contribute to its income through grants and shared revenue agreements. The company is focused on expanding its market presence and product offerings, which could provide additional revenue opportunities in the growing field of neurosurgery.

ClearPoint Neuro Financial Statement Overview

Summary

ClearPoint Neuro shows strong revenue growth and a solid balance sheet with low leverage. However, profitability challenges and negative operating cash flow remain significant concerns.

Income Statement

ClearPoint Neuro has shown a consistent increase in revenue over the years, with a notable revenue growth rate of 31% from 2023 to 2024. However, the company continues to operate at a loss with a negative net profit margin of -60.3% in 2024. The gross profit margin remains strong at 60.9%, indicating efficient cost management relative to revenue. The EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.

Balance Sheet

The company's balance sheet shows improvement in stockholders' equity, which increased to $25.4 million in 2024 from $21.2 million in 2023. The debt-to-equity ratio has improved significantly over the years, standing at 0.14 in 2024, indicating lower leverage risk. The equity ratio is robust at 64.8%, highlighting a strong capital structure. However, the company needs to address its negative net income for better return on equity.

Cash Flow

ClearPoint Neuro's cash flow situation shows a positive trend in free cash flow growth, with free cash flow improving by 37.6% from 2023 to 2024. However, the operating cash flow remains negative, which could impact long-term sustainability. The company has been financing its operations through external funding, as seen in its financing cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	33.59M	31.39M	23.95M	20.55M	16.30M	12.83M
Gross Profit	20.30M	19.12M	13.61M	13.53M	11.29M	9.12M
EBITDA	-21.65M	-17.84M	-20.99M	-15.58M	-12.74M	-4.79M
Net Income	-22.22M	-18.91M	-22.09M	-16.43M	-14.41M	-6.78M
Balance Sheet
Total Assets	62.87M	39.19M	42.66M	55.49M	65.58M	29.64M
Cash, Cash Equivalents and Short-Term Investments	41.54M	20.10M	23.14M	37.49M	54.11M	20.10M
Total Debt	6.61M	3.57M	13.94M	11.99M	12.28M	24.12M
Total Liabilities	43.13M	13.80M	21.49M	18.60M	16.79M	27.26M
Stockholders Equity	19.74M	25.39M	21.17M	36.89M	48.79M	2.38M
Cash Flow
Free Cash Flow	-11.71M	-9.22M	-14.77M	-17.31M	-12.87M	-8.29M
Operating Cash Flow	-11.17M	-8.95M	-13.72M	-16.17M	-12.70M	-7.81M
Investing Cash Flow	-549.00K	-275.00K	8.95M	-10.74M	-168.00K	-482.00K
Financing Cash Flow	20.59M	6.19M	296.00K	409.00K	46.88M	22.69M

ClearPoint Neuro Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 19.74
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLPT, the sentiment is Positive. The current price of 19.74 is above the 20-day moving average (MA) of 12.32, above the 50-day MA of 11.43, and above the 200-day MA of 13.37, indicating a bullish trend. The MACD of 1.88 indicates Negative momentum. The RSI at 90.05 is Negative, neither overbought nor oversold. The STOCH value of 88.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLPT.

ClearPoint Neuro Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TCMD	79 Outperform	310.75M	21.77	7.75%	―	6.15%	-54.24%
CLPT	60 Neutral	$548.08M	―	-85.68%	―	19.68%	-13.17%
VREX	57 Neutral	508.79M	-3.69	-29.10%	―	-1.36%	-479.49%
NPCE	54 Neutral	338.09M	-12.01	-338.71%	―	23.32%	23.29%
PACB	41 Neutral	375.46M	-0.54	-61.16%	―	-17.35%	-19.34%
NNOX	40 Underperform	252.50M	-4.17	-28.30%	―	17.36%	9.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

ClearPoint Neuro Corporate Events

ClearPoint Neuro Reports Record Q2 Revenue Growth

On August 12, 2025, ClearPoint Neuro reported its second quarter financial results, highlighting a record revenue of $9.2 million, marking a 17% increase from the previous year. The company also secured a substantial cash infusion through a financing arrangement and stock purchase agreement with Oberland Capital Management, enhancing its cash position to $41.5 million. The growth was driven by increased sales in neurosurgery navigation and therapy, particularly from SmartFrame® Family Navigation devices and ClearPoint PRISM® Laser Therapy Applicators. ClearPoint Neuro’s strategic ‘Fast. Forward.’ phase aims to expand its operations across multiple growth vectors, including operating room expansion, laser therapy, regulatory approvals, and partnerships with BioPharma, positioning the company for continued growth and innovation in the industry.

The most recent analyst rating on (CLPT) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.

ClearPoint Neuro Expands with New Lease Agreement

On June 16, 2025, ClearPoint Neuro, Inc. entered into a lease agreement with BRE-BMR SCD LLC to expand into a 30,171 square foot life science building in San Diego, California. This expansion will be executed in three phases, with the first phase expected to be occupied by June 13, 2025, and the final phase by July 1, 2026. The lease term is set for 132 months from the last phase’s occupation, with an option to extend for an additional five years. The initial monthly base rent is $5.95 per square foot, with specific abatement periods and annual increases of 3%. ClearPoint Neuro is also responsible for operating expenses and must provide a letter of credit as security.

The most recent analyst rating on (CLPT) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.